Biomanufacturing Innovation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Biomanufacturing Innovation
The industry wants more innovation, but can suppliers meet customers' needs?


Pharmaceutical Technology Europe
Volume 24, Issue 6


Eric Langer
The biopharmaceutical industry has a voracious appetite for new technologies that increase productivity and improve performance, a point confirmed by BioPlan Associates' annual survey on bioprocessing trends and innovation (1).

Bioprocessing innovations in demand


Figure 1: Select new product and service areas of interest, 2010–2012.
When asked about average budget changes from 2009–2012, those surveyed reported the highest budget increases were for new technologies to improve efficiencies and costs for downstream production (an average 6.4% increase) and for upstream production (an average 6.0% increase). For new products, the largest portion of respondents cited disposable bags and connectors (40.0%), followed by probes and sensors, (36.1%), chromatography products (32.2%), bioreactors (31.7%) and purification products (28.9%) (see Figure 1). Much of the interest in improved sensors, bioreactor, purification and other equipment involves single-use applications. Only 10% of respondents wanted new stainless steel equipment. In services, upstream process development services topped the list.

The survey showed that a common cause for dissatisfaction with current single-use bioreactors, liners and other equipment that is not robust enough. Single-use equipment is still not adaptable to the more extreme mixing, heat and other conditions involved with most microbial systems (e.g., E. coli and yeast).

When asked to rate the factors responsible for creating bioprocessing improvements in the last 12 months, the largest portion (72.6%) cited "overall better control of processes," followed by "improved downstream production operations," and "use of disposable/single-use devices."

Vendors' focus on R&D


Figure 2: The top six new technologies being worked on by vendors, 2010 – 2012.
To evaluate how well vendors' R&D match industry needs, the BioPlan survey asked about budget changes in 2012. Vendor respondents reported an average 1.9% increase in basic R&D for product development, a 2.4% increase for hiring new staff, a 4.3% gain in sales budgets and a 3.4% uptick in capital-equipment purchases. Survey data show vendors concentrating much of their R&D on improved and new single-use equipment (see Figure 2)

The largest portion (46.2%) report working on bioprocess development/optimisation services and bioprocess modeling, followed by disposable/single-use bioreactors and consumables, single-use bags and films, filtration and chromatography products. Other examples of vendor R&D include: animal-free media components; bioreactor control; chromatography alternatives to Protein A; cell- line optimisation; sensors and probes; culture-media optimisation services; alternative mammalian-cell expression systems; monitoring systems; culture-media supplements; controller systems; impurities detection; bacterial expression systems; lyophilisation; testing/assay services (e.g., raw materials, glycosylation, viral clearance, cell lines); and packaging materials.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here